Shanghai Fosun Pharmaceutical (Group) Yönetim

Yönetim kriter kontrolleri 2/4

Shanghai Fosun Pharmaceutical (Group) CEO'su Deyong Wen, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı CN¥ 10.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.9% maaş ve 74.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.004% ine doğrudan sahiptir ve bu hisseler CN¥ 2.53M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 3.4 yıldır.

Anahtar bilgiler

Deyong Wen

İcra Kurulu Başkanı

CN¥10.0m

Toplam tazminat

CEO maaş yüzdesi	25.9%
CEO görev süresi	2.8yrs
CEO sahipliği	0.004%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Aug 03

Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Jul 28

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

May 23

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26

CEO Tazminat Analizi

Deyong Wen'un ücretlendirmesi Shanghai Fosun Pharmaceutical (Group)'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥10m	CN¥3m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥8m	CN¥2m	CN¥4b

Tazminat ve Piyasa: Deyong 'nin toplam tazminatı ($USD 1.41M ), CN pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 269.95K ).

Tazminat ve Kazançlar: Deyong şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Deyong Wen (53 yo)

2.8yrs

Görev süresi

CN¥9,997,000

Tazminat

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kexin Wang	Executive Co-Chairman	2.9yrs	CN¥15.25m	0.012% CN¥ 8.0m
Yifang Wu	Executive Chairman	8.3yrs	CN¥12.14m	0.045% CN¥ 29.6m
Deyong Wen	Joint President	2.8yrs	CN¥10.00m	0.0039% CN¥ 2.5m
Xiaohui Guan	Executive Vice Chairman	2.9yrs	CN¥9.14m	0.011% CN¥ 7.2m
Rongli Feng	Executive President & Chief Human Resources Office	less than a year	Veri yok	0.0043% CN¥ 2.8m
Jing Li	Executive President and CEO of Established Medicines Manufacturing & Supply Division	no data	Veri yok	0.0043% CN¥ 2.8m
Wang Xingli	Executive President	1.8yrs	Veri yok	Veri yok
Wenjie Zhang	Executive President & Co-CEO of Innovative Drug Division	1.8yrs	Veri yok	Veri yok
Zhanyu Chen	Senior VP & CFO	less than a year	Veri yok	Veri yok
Jia Yan	Director of the Accounting Department	no data	Veri yok	Veri yok
Dongjiu Li	Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee	3.7yrs	Veri yok	0.0025% CN¥ 1.6m
Donghua Wang	Senior VP & Chief Strategic Enabler	4.1yrs	Veri yok	0.0043% CN¥ 2.8m

2.1yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 600196 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kexin Wang	Executive Co-Chairman	2.9yrs	CN¥15.25m	0.012% CN¥ 8.0m
Yifang Wu	Executive Chairman	8.3yrs	CN¥12.14m	0.045% CN¥ 29.6m
Deyong Wen	Joint President	2.3yrs	CN¥10.00m	0.0039% CN¥ 2.5m
Xiaohui Guan	Executive Vice Chairman	2.9yrs	CN¥9.14m	0.011% CN¥ 7.2m
Guliang Tang	Independent Non-Executive Director	5.4yrs	CN¥392.00k	Veri yok
Qiyu Chen	Non-Executive Director	19.5yrs	Veri yok	0.0043% CN¥ 2.8m
Xiaoliang Xu	Non-Executive Director	5.4yrs	Veri yok	Veri yok
Ling Li	Independent Non-Executive Director	5.4yrs	CN¥392.00k	Veri yok
Tze Shan Yu	Independent Non-Executive Director	3.4yrs	CN¥392.00k	Veri yok
Yuqing Chen	Non-Executive Director	less than a year	Veri yok	0.0058% CN¥ 3.8m
Quandi Wang	Independent Non-Executive Director	3.4yrs	CN¥392.00k	Veri yok
Bing Chen	Chief Supervisor	1.4yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600196 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Shanghai Fosun Pharmaceutical (Group) Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 24%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces in Relation to the Approval for Drug Registration of Licensed Product

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Dividend reduced to CN¥0.27

Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

Consensus EPS estimates fall by 12%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Consensus EPS estimates fall by 17%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Profit margin trend

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Price target decreased by 13% to CN¥32.65

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Price target decreased by 7.0% to CN¥37.41

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.42 in 2Q 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Less than half of directors are independent

Consensus forecasts updated

Investor sentiment improved over the past week

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Third quarter 2022 earnings: Revenues exceed analyst expectations

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Executive Vice Chairman recently bought CN¥391k worth of stock

Now 20% undervalued after recent price drop

Executive Chairman recently bought CN¥887k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Price target decreased to CN¥46.32

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥50.41

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥56.55

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022